Hormonal
GLP-1 receptor agonists (liraglutide and exenatide) produce significant weight loss and BMI reduction in women with PCOS, alongside improvements in metabolic and cardiovascular risk markers.
For women with PCOS and obesity, GLP-1 agonists like liraglutide and exenatide are effective for weight loss and improving metabolic health. Treatment involves starting at a low dose to manage side effects like nausea, then titrating up to the therapeutic dose (1.8mg for Liraglutide, 10mcg BID for Exenatide) over several weeks. This should be combined with lifestyle changes.
The included studies uniformly reported reductions in weight and body mass index (BMI) among patients who were prescribed GLP-1 RAs, specifically liraglutide or exenatide. Additionally, evidence pointed towards improvements in anthropometric parameters (including total body weight, BMI, reduction in waist circumference, and total fat percentage), glucose homeostasis, cardiovascular inflammatory markers...
Why this rating
Based on a scoping review of 8 studies (5 RCTs, 3 quasi-experimental) with mixed risk of bias.
Source
Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
Melissa Frangie Machado et al. · Cureus · 2024
DOI 10.7759/cureus.66691
More from this paper
- GLP-1 receptor agonists improve reproductive outcomes in women with PCOS, including increased menstrual regularity and spontaneous pregnancy rates, by reducing androgen levels and improving insulin resistance.Moderate
- GLP-1 receptor agonists improve cardiovascular risk markers in women with PCOS, including reductions in inflammatory markers (CRP) and improvements in endothelial function, although effects on lipid profiles are inconsistent.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →